Ann: Unilife - SPP Applications , page-2

A total of A$21.5 million to be accepted under this Unilife SPP
Unilife Medical Solutions Limited (ASX:UNI/OTCPK:UNIFF),(Unilife or the Company) is pleased to
announce that its 2009 Share Purchase Plan (SPP), which closed on Friday, 30 October 2009, was
significantly oversubscribed with applications for approximately 33.7 million new, fully paid ordinary
shares (SPP Shares) with a value of approximately A$28.7 million.
As a result of the overwhelming demand for Shares under the SPP, the Board has authorised an
increase in the number of Shares to be issued under the SPP from 11,764,705 Shares to raise
$10 million to approximately 25.3 million Shares, to raise approximately A$21.5 million before costs,
representing a pro-rata allotment to all shareholders of 75% of their application.
As announced on 7 October 2009, Unilife offered eligible shareholders with a registered address in
Australia or New Zealand the opportunity to subscribe for up to $15,000 worth of Shares under the
SPP. In accordance with ASIC Class Order 09/425, applications by individual shareholders for
more than A$15,000 worth of Shares have been rejected and, as a result of the over-subscription,
the Company will scale back other applications, such that each applicant will receive 75% of their
initial application for Shares under the SPP. Unilife will refund any excess application remittances
to shareholders (without interest) shortly following allotment of the SPP Shares which is now due to
occur on 17 November 2009.
In addition to the receipt of commitments for A$32.1 million from institutional investors in the US and
sophisticated and professional investors in Australia, the Board decision to increase the amount to
be accepted under the SPP to A$21.5 million has resulted in the total sum committed amounting to
A$53.6 million.
The additional funds accepted under this SPP will further help Unilife accelerate the continued
expansion of its business activities within the United States and other international markets. In
particular, the Board expects that these additional funds will assist the Company with the
development of its new global headquarters and production facility to be established in Central
Pennsylvania, and fast-track the development of production systems that will support anticipated
pharmaceutical market demand for its range of Unifill syringes.